Evidence and implications of haemoglobin cycling in anaemia management

Nephrology Dialysis Transplantation

Volumn 22, Issue 8, 2007, Pages 2129-2132

  Fishbane, Steven ^a   Berns, Jeffrey S ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anaemia; Chronic kidney disease; Erythropoiesis stimulating agents; Haemoglobin

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG RESPONSE; FLUID BALANCE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; IRON THERAPY; PRIORITY JOURNAL; REVIEW;

ANEMIA; CHRONIC DISEASE; COMORBIDITY; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; NEPHROLOGY;

EID: 34547843596     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm384     Document Type: Review

References (23)

1. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343
2. Macdougall IC, Wilson P, Roche A. Impact of haemoglobin variability in haemodialysis patients receiving erythropoiesis-stimulating agents for the management of renal anaemia. J Am Soc Nephrol 2005; 16: 899A
3. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-1210
4. Lacson E, Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-124
5. Collins AJ, Brenner RM, Ofman JJ et al. Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 481-488
6. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37[Suppl 1]: S182-S238
7. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, DeOreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
8. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000
9. Drüeke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16[Suppl 7]: 25-28
10. Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 2004; 66: 2429-2436
11. Bellizzi V, Minutolo R, Terracciano V et al. Influence of cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 2002; 40: 549-555
12. Minutolo R, DiNicola L, Bellizzi V et al. Intra- and post-dialytic changes in haemoglobin concentrations in non-anaemic haemodialysis patients. Nephrol Dial Transpl 2003; 18: 2606-2612
13. Berns JS. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Semin Dial 2005; 18: 22-29
14. Cain SM. Oxygen delivery and uptake in dogs during anemic and hypoxic hypoxia. J Appl Physiol 1977; 42: 228-234
15. Fishbane S. Recombinant human erythropoietin: Has treatment reached its full potential? Semin Dial 2006; 19: 1-4
16. Feldman HI, Israni RK, Yang W, Fishbane S, Joffe M. Hemoglobin variability (HgbVar) and mortality among hemodialyisis patients [abstract]. J Am Soc Nephrol 2006; 17: 583A
17. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17: 1181-1191
18. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the Year 2010. J Am Soc Nephrol 2001; 12: 2753-2758
19. Roderick P, Davies R, Jones C, Feest T, Smith S, Farrington K. Simulation model of renal replacement therapy: Predicting future demand in England. Nephrol Dial Transplant 2004; 19: 692-701
20. U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005
21. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47 [Suppl 3]: S11-S145
22. Drueke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
23. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098